imipramine has been researched along with Diabetes Mellitus, Type 2 in 3 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-three elderly patients with type 2 diabetes and hypomagnesemia were enrolled and randomly allocated to receive either 50 mL of MgCl2 5% solution equivalent to 450 mg of elemental magnesium or Imipramine 50 mg daily during 12 weeks." | 2.73 | Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. ( Barragán-Rodríguez, L; Guerrero-Romero, F; Rodríguez-Morán, M, 2008) |
| "Depression is a major comorbidity factor of diabetes and the outcome of one disorder influences the other." | 1.43 | Evidence for the involvement of neuropeptide Y in the antidepressant effect of imipramine in type 2 diabetes. ( Bharne, AP; Kokare, DM; Nakhate, KT; Subhedar, NK; Yedke, SU, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakhate, KT | 1 |
| Yedke, SU | 1 |
| Bharne, AP | 1 |
| Subhedar, NK | 1 |
| Kokare, DM | 1 |
| Barragán-Rodríguez, L | 1 |
| Rodríguez-Morán, M | 1 |
| Guerrero-Romero, F | 1 |
| Derijks, HJ | 1 |
| De Koning, FH | 1 |
| Meyboom, RH | 1 |
| Heerdink, ER | 1 |
| Spooren, PF | 1 |
| Egberts, AC | 1 |
1 trial available for imipramine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial.
Topics: Aged; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Humans; Imipramine; Magnesium; M | 2008 |
2 other studies available for imipramine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Evidence for the involvement of neuropeptide Y in the antidepressant effect of imipramine in type 2 diabetes.
Topics: Animals; Antidepressive Agents, Tricyclic; Arginine; Blood Glucose; Central Amygdaloid Nucleus; Depr | 2016 |
Impaired glucose homeostasis after imipramine intake in a diabetic patient.
Topics: Antidepressive Agents, Tricyclic; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationsh | 2005 |